Taglich's Company Profile for:
New information will be posted soon...
Pivotal Therapeutics Inc., (PVTTF.PK) headquartered in Woodbridge, Ontario, Canada was established in 2010. Pivotal is a development stage specialty pharmaceutical company that is currently focused on the commercialization of Vascazen, an FDA-approved prescription Omega 3 medical food product developed to reduce risk factors that lead to adverse coronary events, including sudden death. Vascazen is the first of a range of proven formulations that Pivotal envisions taking to market while avoiding the costly regulatory review (New Drug Applications and Abbreviated New Drug Applications) that prescription drugs are subject to.
Clinical studies prove that Omega 3, commonly referred to as fish oil, significantly reduces cardiovascular risk factors stemming from dietary deficiencies in fish oils. Omega 3 is particularly effective when formulated, as Vascazen is, with high concentrations of eicosapentaenoic acid (EPA) and docosahexanenoic acid (DHA) in optimally balanced proportions.
All Research Reports are in Adobe Acrobat format.
For the latest Adobe Acrobat reader click here)
The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statements are the opinion of Taglich Brothers, Inc. and are not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in the reports are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned and was not a manager or co-manager of any offering for the company within the last three years. In December 2011 the company paid an initial monetary engagement fee of US$5,250 to Taglich Brothers, Inc. representing payment for the first three months of creation and dissemination of research reports, after which the company will pay Taglich Brothers, Inc. a monetary fee of US$1,750 per month for a minimum of three more months for such services.
Send to a Friend
To send this page to a friend, just fill out the form below
and press the "send it" button!